Mirum(MIRM) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, the company achieved $521 million in net product sales, a 55% increase from $336 million in 2024 [5][14] - The fourth quarter of 2025 saw net product sales of $149 million, compared to $99 million in the same quarter of the previous year [14] - The company ended 2025 with $391 million in cash equivalents, up from $293 million at the end of 2024 [15] Business Line Data and Key Metrics Changes - LIVMARLI net product sales were $245 million in the U.S. and $115 million internationally, with bile acid medicines contributing an additional $161 million [5] - The commercial cash contribution margin in 2025 was approximately 55%, a significant increase from the prior year [15] Market Data and Key Metrics Changes - The company expects net product sales for 2026 to be between $630 million and $650 million, indicating continued growth [6] - The company anticipates a return to positive cash flow in 2027, following increased R&D expenses in 2026 [16] Company Strategy and Development Direction - The company is focused on advancing its pipeline with multiple clinical and regulatory milestones, including the approval of Ctexli for CTX and a tablet formulation of LIVMARLI [6][7] - The addition of the phase III brelovitug program for chronic hepatitis delta virus aligns with the company's strategy to address significant unmet needs in rare diseases [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026, highlighting a strong commercial business and a robust pipeline with four potentially pivotal readouts expected in the next 18 months [17] - The company is committed to disciplined execution and delivering impactful medicines for patients with rare diseases [9][17] Other Important Information - The company completed two private placements concurrent with the closing of the Bluejay acquisition, generating gross proceeds of $268.5 million [15] - The company is on track to report top-line data from the volixibat VISTA study in PSC in the second quarter of 2026 [10][11] Q&A Session Summary Question: Volixibat pricing strategy - Management indicated that pricing considerations for volixibat will be based on data closer to launch, noting its unique positioning due to the lack of approved medicines for PSC [19][20] Question: Risk factors in PSC trial - Management acknowledged the episodic nature of pruritus in PSC patients and emphasized the study design's focus on enrolling patients with persistent pruritus to limit variability [25][28] Question: Similarities between VISTA and VANTAGE study designs - Management highlighted commonalities in studying cholestatic pruritus and confirmed that patients with moderate to severe pruritus will be selected for both studies [35][36] Question: FDA interactions regarding safety database for volixibat - Management confirmed that the current VISTA study has a sufficient safety database and plans to interact with the FDA regarding the submission plan after top-line data [40] Question: Market for hepatitis delta virus (HDV) - Management noted the evolving landscape for HDV treatments and expressed optimism about brelovitug's potential as a best-in-class option [70][71] Question: R&D spending increase for HDV studies - Management anticipates a $150 million increase in R&D spending related to the brelovitug program, with significant investments in CMC [72]